Ginsenosides Decrease β-Amyloid Production via Potentiating Capacitative Calcium Entry
10.4062/biomolther.2023.172
- Author:
Yoon Young CHO
1
;
Jeong Hill PARK
;
Jung Hee LEE
;
Sungkwon CHUNG
Author Information
1. Department of Physiology, Sungkyunkwan University School of Medicine, Suwon 16419, Republic of Korea
- Publication Type:Original Article
- From:Biomolecules & Therapeutics
2024;32(3):301-308
- CountryRepublic of Korea
- Language:EN
-
Abstract:
Alzheimer’s disease (AD) is a progressive and irreversible neurodegenerative disorder characterized by extracellular amyloid plaques composed of amyloid β-peptide (Aβ). Studies have indicated that Ca 2+ dysregulation is involved in AD pathology. It is reported that decreased capacitative Ca 2+ entry (CCE), a refilling mechanism of intracellular Ca 2+ , resulting in increased Aβ production. In contrast, constitutive activation of CCE could decrease Aβ production. Panax ginseng Meyer is known to enhance memory and cognitive functions in healthy human subjects. We have previously reported that some ginsenosides decrease Aβ levels in cultured primary neurons and AD mouse model brains. However, mechanisms involved in the Aβ-lowering effect of ginsenosides remain unclear. In this study, we investigated the relationship between CCE and Aβ production by examining the effects of various ginsenosides on CCE levels. Aβ-lowering ginsenosides such as Rk1, Rg5, and Rg3 potentiated CCE. In contrast, ginsenosides without Aβ-lowering effects (Re and Rb2) failed to potentiate CCE. The potentiating effect of ginsenosides on CCE was inhibited by the presence of 2-aminoethoxydiphenyl borate (2APB), an inhibitor of CCE. 2APB alone increased Aβ42 production. Furthermore, the presence of 2APB prevented the effects of ginsenosides on Aβ42 production. Our results indicate that ginsenosides decrease Aβ production via potentiating CCE levels, confirming a close relationship between CCE levels and Aβ production. Since CCE levels are closely related to Aβ production, modulating CCE could be a novel target for AD therapeutics.
